Currently, there are 2.26M common shares owned by the public and among those 2.22M shares have been available to trade.
The company’s stock has a 5-day price change of 19.29% and -41.61% over the past three months. GLMD shares are trading -47.65% year to date (YTD), with the 12-month market performance down to -65.21% lower. It has a 12-month low price of $1.21 and touched a high of $23.80 over the same period. GLMD has an average intraday trading volume of 867.59K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 17.07%, -9.88%, and -48.30% respectively.
Institutional ownership of Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) shares accounts for 9.39% of the company’s 2.26M shares outstanding.
It has a market capitalization of $3.78M and a beta (3y monthly) value of 0.45. The earnings-per-share (ttm) stands at -$9.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 19.94% over the week and 14.73% over the month.
Earnings per share for the fiscal year are expected to increase by 64.49%, and 73.93% over the next financial year. EPS should grow at an annualized rate of 62.35% over the next five years, compared to 45.91% over the past 5-year period.
Looking at the support for the GLMD, a number of firms have released research notes about the stock. B. Riley FBR stated their Neutral rating for the stock in a research note on May 22, 2020, with the firm’s price target at $11-$8. Craig Hallum coverage for the Galmed Pharmaceuticals Ltd (GLMD) stock in a research note released on February 04, 2020 offered a Buy rating with a price target of $18. B. Riley FBR on their part issued Buy rating on December 12, 2018.
